Navigation Links
Prometheus Launches MyCeliacID(TM), the First Do it Yourself, Saliva-Based Genetic Test Dedicated to Celiac Disease
Date:6/29/2009

SAN DIEGO, June 29 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the launch of MyCeliacID(TM), the first do it yourself, saliva-based genetic test dedicated to celiac disease. MyCeliacID identifies distinct genetic sequences associated with celiac disease, a largely undiagnosed genetic disorder that affects approximately 3 million people in the United States. MyCeliacID is the saliva-based version of a blood test used by doctors. The test can be ordered online at www.MyCeliacID.com.

"Prometheus is a leader in celiac genetic testing, performing more than 80,000 blood-based genetic tests for celiac disease to date," said Ron Rocca, Prometheus' General Manager, Gastrointestinal Products. "An estimated 1% of people in the United States live with celiac disease however many remain undiagnosed. We have decided to make MyCeliacID, a highly-reliable, non-invasive, DNA-based test for celiac disease, available directly to the public so that people who are searching for answers can have better information about their condition."

Celiac disease appears in individuals genetically predisposed to the disease and who consume gluten, a protein found in grains such as wheat, barley and rye. MyCeliacID is the only test that provides individuals with their risk of developing the disease relative to the general population. In addition, MyCeliacID can virtually rule out celiac disease in a person's lifetime. A negative test result indicates that the individual does not have the genes associated with celiac disease and is highly unlikely to develop the disease. A positive result indicates that the individual has one or more genes that predispose to celiac disease, however it is not an indication of the disease itself. Individuals with a positive test result should see a physician, who may elect to perform other testing. Only a doctor can diagnose celiac disease.

"When my son Tyler was diagnosed in 1991, genetic testing for celiac disease wasn't available," said Danna Korn, founder of Raising Our Celiac Kids (ROCK) and author of four best-selling books, including Living Gluten-Free for Dummies. "It took two frustrating years of searching for answers and for the cause of my son's symptoms. Today, with MyCeliacID, you can quickly find out if you or a loved one has the genes for celiac disease."

MyCeliacID is available online. A licensed physician will review and place the order in accordance with state and federal law after a test request is made online. In addition, after the testing is performed, the physician will review and release the result. Test results can be accessed online via a secure link, usually within 7 days from receipt of the saliva sample.

About Celiac

Celiac disease is an immune-mediated digestive disease that is triggered by the consumption of gluten and damages the small intestine, interfering with the absorption of nutrients from food. Symptoms of celiac disease may vary significantly from person to person and include, but are not limited to, diarrhea, anemia, abdominal pain, skin rash and weight loss. The number of diagnosed patients is expected to increase significantly over the next several years, driven by broad-based educational campaigns, National Institutes of Health research funding and widely-available genetic and blood tests for highly-specific antibodies.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is extra-corporal liver support with prometheus safe in patients with end-stage liver disease?
2. Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting
3. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
4. UPMC Health Plan Launches New Personal Health Record
5. HealthInsuranceFinders.com Launches Video Contest for Young Directors
6. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
7. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. Mannatech Launches Phase One of New Sales and Training Tools
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. Actavis Launches Carvedilol Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: